Skip to main content
European Commission logo
English
TBT - European Commission

Notification Detail

Draft Commission Implementing Decision (EU) not renewing the approval of medetomidine as an active substance for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

G/TBT/N/EU/1220

Date of arrival: 2026 July 08
-
Final date for comments: 2026 September 06
Description
This draft Commission Implementing Decision does not renew the approval of medetomidine as an active substance for use in biocidal products of product-type 21. Medetomidine has endocrine disrupting properties that may cause adverse effects in humans in accordance with the criteria laid down in Commission Delegated Regulation (EU) 2017/2100[1]. Medetomidine therefore meets the exclusion criterion set out in Article 5(1), point (d), of Regulation (EU) No 528/2012. Alternatives are available for its use in biocidal products of product-type 21. None of the derogation criteria under Article 5(2) of the BPR are considered met. It is therefore appropriate not to renew the approval of medetomidine as an active substance for use in biocidal products of product-type 21. The opinion of the European Chemicals Agency can be found on its website (Biocidal Products Committee opinions on active substance approval - ECHA (europa.eu).
Objectives:
  • Protection of Environment
Fields of Activity:
  • Products of the chemical industry
Full notification form text:
Full text of the announced text or any other relevant text:
Comments, answers or reactions:
Disclaimer: Please note that the information published is not necessarily comprehensive. In particular, documents of notifications dated before 1 January 2014, and comments and answers received or sent on TBT notifications before 1 January 2018 are not publicly available due to data protection requirements. Some comments and answers received or sent after 1 January 2018 may be unavailable also for data protection reasons.